DK3712131T3 - Neurotensinreceptorligander - Google Patents
Neurotensinreceptorligander Download PDFInfo
- Publication number
- DK3712131T3 DK3712131T3 DK20166422.4T DK20166422T DK3712131T3 DK 3712131 T3 DK3712131 T3 DK 3712131T3 DK 20166422 T DK20166422 T DK 20166422T DK 3712131 T3 DK3712131 T3 DK 3712131T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor ligands
- neurotensin receptor
- neurotensin
- ligands
- receptor
- Prior art date
Links
- 102000017922 Neurotensin receptor Human genes 0.000 title 1
- 108060003370 Neurotensin receptor Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12008208.6A EP2740726A1 (en) | 2012-12-07 | 2012-12-07 | Neurotensin receptor ligands |
| EP13814827.5A EP2928870B1 (en) | 2012-12-07 | 2013-12-06 | Neurotensin receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3712131T3 true DK3712131T3 (da) | 2023-03-20 |
Family
ID=47355771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13814827.5T DK2928870T3 (da) | 2012-12-07 | 2013-12-06 | Neurotensin-receptorligander |
| DK20166422.4T DK3712131T3 (da) | 2012-12-07 | 2013-12-06 | Neurotensinreceptorligander |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13814827.5T DK2928870T3 (da) | 2012-12-07 | 2013-12-06 | Neurotensin-receptorligander |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10961199B2 (da) |
| EP (3) | EP2740726A1 (da) |
| JP (2) | JP6576828B2 (da) |
| KR (1) | KR102290803B1 (da) |
| CN (2) | CN104837819B9 (da) |
| AU (1) | AU2013354422B2 (da) |
| BR (1) | BR112015012530B1 (da) |
| CA (1) | CA2893605C (da) |
| DK (2) | DK2928870T3 (da) |
| ES (2) | ES2941629T3 (da) |
| FI (1) | FI3712131T3 (da) |
| HK (1) | HK1210148A1 (da) |
| HU (2) | HUE050388T2 (da) |
| IL (1) | IL239080B (da) |
| MX (1) | MX370354B (da) |
| PL (2) | PL2928870T3 (da) |
| PT (2) | PT2928870T (da) |
| RU (1) | RU2671970C2 (da) |
| SG (2) | SG10201704564QA (da) |
| WO (1) | WO2014086499A1 (da) |
| ZA (1) | ZA201503446B (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015188934A1 (en) * | 2014-06-10 | 2015-12-17 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| EP2954934A1 (en) * | 2014-06-11 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand and use thereof |
| EP2954933A1 (en) * | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand |
| DK3380495T3 (da) * | 2015-11-24 | 2021-08-16 | Transfert Plus Sec | Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi |
| EP3279197A1 (en) | 2016-08-03 | 2018-02-07 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnosis, treatment and prevention of neurotensin receptor-related conditions |
| JP7105235B2 (ja) | 2016-12-01 | 2022-07-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔイメージングのための放射性標識された抗ｐｄ－ｌ１抗体 |
| MX2019009565A (es) | 2017-02-10 | 2020-02-24 | Regeneron Pharma | Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet. |
| AU2018307744A1 (en) | 2017-07-24 | 2020-02-13 | Regeneron Pharmaceuticals, Inc. | Anti-CD8 antibodies and uses thereof |
| KR20220032079A (ko) * | 2019-07-08 | 2022-03-15 | 쓰리비 파마슈티컬스 게엠베하 | 섬유모세포 활성화 단백질 리간드를 포함하는 화합물 및 그의 용도 |
| CN111875667B (zh) * | 2020-07-16 | 2021-12-21 | 南方科技大学 | 有机金属螯合物及其制备方法与应用、探针 |
| MX2023004715A (es) * | 2020-10-22 | 2023-05-10 | Nihon Mediphysics Co Ltd | Metodo para producir un complejo de circonio radioactivo. |
| KR20240007257A (ko) * | 2021-05-13 | 2024-01-16 | 더 제너럴 하스피탈 코포레이션 | 알데히드의 생체내 검출을 위한 분자 프로브 |
| EP4355325A1 (en) * | 2021-06-16 | 2024-04-24 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and folfirinox |
| WO2022261771A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel |
| JP2025503213A (ja) * | 2022-01-28 | 2025-01-30 | フュージョン ファーマシューティカルズ インコーポレイテッド | Ｎｔｓｒ１標的化放射性医薬品およびチェックポイント阻害剤併用療法 |
| CN119136796A (zh) | 2022-02-18 | 2024-12-13 | 辐联科技香港有限公司 | 靶向神经降压素受体的化合物和放射性配体及其用途 |
| AU2023264077A1 (en) * | 2022-05-03 | 2024-11-14 | The University Of North Carolina At Chapel Hill | Development of ntsr targeted agents for imaging and therapy applications |
| US12091454B2 (en) | 2022-12-28 | 2024-09-17 | Development Center For Biotechnology | Humanized anti-human neurotensin receptor 1 antibodies and their uses |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110321A (en) | 1976-07-12 | 1978-08-29 | Folkers Karl | Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity |
| US4425269A (en) | 1982-06-07 | 1984-01-10 | Merck & Co., Inc. | Metabolically protected analogs of neurotensin |
| US4439359A (en) | 1982-07-02 | 1984-03-27 | Merck & Co., Inc. | Cyclic octapeptide analogs of neurotensin |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| FR2665898B1 (fr) | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| CA2086453A1 (en) | 1992-12-30 | 1994-07-01 | Mcgill University | Marker for neurotensin receptor |
| US5407916A (en) | 1993-02-16 | 1995-04-18 | Warner-Lambert Company | Neurotensin mimetics as central nervous system agents |
| FR2711140B1 (fr) * | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
| JPH11514329A (ja) | 1994-02-18 | 1999-12-07 | マリンクロット・メディカル・インコーポレイテッド | 標識化ペプチド化合物 |
| US6054557A (en) | 1995-04-04 | 2000-04-25 | Advanced Bioconcept (1994) Ltd. | Fluorescent peptides |
| EP0820466A2 (en) | 1995-04-04 | 1998-01-28 | Advanced Bioconcept Inc. | Fluorescent peptides |
| FR2732967B1 (fr) | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
| AU6352296A (en) | 1995-07-20 | 1997-02-18 | Advanced Bioconcept, Inc. | Cell sorting with fluorescent peptides |
| EP0968001B1 (en) | 1997-02-03 | 2003-11-05 | Mallinckrodt Inc. | Method for the detection and localization of malignant human pancreatic tumours |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| US6214790B1 (en) | 1998-04-10 | 2001-04-10 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| EP1194444A2 (en) | 1999-06-24 | 2002-04-10 | BioSynthema Inc. | Labeled neurotensin derivatives with improved resistance to enzymatic degradation |
| EP2338525A3 (en) * | 2003-07-09 | 2011-08-03 | California Pacific Medical Center | Remote detection of substance delivery to cells |
| US20060062729A1 (en) * | 2004-09-09 | 2006-03-23 | Carraway Robert E | Enhanced ligand binding to neurotensin receptors |
| WO2008091530A2 (en) * | 2007-01-19 | 2008-07-31 | Mallinckrodt Inc. | Diagnostic and therapeutic cyclooxygenase-2 binding ligands |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| WO2010033196A2 (en) * | 2008-09-16 | 2010-03-25 | The Regent Of The University Of California | Simplified one-pot synthesis of [18f]sfb for radiolabeling |
| CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| US8586043B2 (en) * | 2009-01-07 | 2013-11-19 | Inserm ( Institut National De La Sante Et De La Recherche Medicale) | Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1 |
| US9809624B2 (en) | 2009-07-16 | 2017-11-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors |
| WO2011156557A2 (en) * | 2010-06-11 | 2011-12-15 | Thomas James B | Compounds active at the neurotensin receptor |
-
2012
- 2012-12-07 EP EP12008208.6A patent/EP2740726A1/en not_active Withdrawn
-
2013
- 2013-12-06 HU HUE13814827A patent/HUE050388T2/hu unknown
- 2013-12-06 MX MX2015007193A patent/MX370354B/es active IP Right Grant
- 2013-12-06 SG SG10201704564QA patent/SG10201704564QA/en unknown
- 2013-12-06 US US14/650,437 patent/US10961199B2/en active Active
- 2013-12-06 PL PL13814827T patent/PL2928870T3/pl unknown
- 2013-12-06 PL PL20166422.4T patent/PL3712131T3/pl unknown
- 2013-12-06 KR KR1020157018171A patent/KR102290803B1/ko active Active
- 2013-12-06 DK DK13814827.5T patent/DK2928870T3/da active
- 2013-12-06 WO PCT/EP2013/003700 patent/WO2014086499A1/en active Application Filing
- 2013-12-06 ES ES20166422T patent/ES2941629T3/es active Active
- 2013-12-06 DK DK20166422.4T patent/DK3712131T3/da active
- 2013-12-06 CN CN201380063364.8A patent/CN104837819B9/zh active Active
- 2013-12-06 EP EP13814827.5A patent/EP2928870B1/en active Active
- 2013-12-06 SG SG11201503880YA patent/SG11201503880YA/en unknown
- 2013-12-06 EP EP20166422.4A patent/EP3712131B1/en active Active
- 2013-12-06 ES ES13814827T patent/ES2795923T3/es active Active
- 2013-12-06 BR BR112015012530-1A patent/BR112015012530B1/pt active IP Right Grant
- 2013-12-06 RU RU2015127086A patent/RU2671970C2/ru active
- 2013-12-06 HU HUE20166422A patent/HUE061839T2/hu unknown
- 2013-12-06 CA CA2893605A patent/CA2893605C/en active Active
- 2013-12-06 CN CN201811305966.0A patent/CN109320502B/zh active Active
- 2013-12-06 FI FIEP20166422.4T patent/FI3712131T3/fi active
- 2013-12-06 JP JP2015545697A patent/JP6576828B2/ja active Active
- 2013-12-06 PT PT138148275T patent/PT2928870T/pt unknown
- 2013-12-06 PT PT201664224T patent/PT3712131T/pt unknown
- 2013-12-06 AU AU2013354422A patent/AU2013354422B2/en active Active
-
2015
- 2015-05-18 ZA ZA2015/03446A patent/ZA201503446B/en unknown
- 2015-05-28 IL IL239080A patent/IL239080B/en active IP Right Grant
- 2015-11-03 HK HK15110838.8A patent/HK1210148A1/xx unknown
-
2019
- 2019-08-21 JP JP2019150947A patent/JP7042776B2/ja active Active
-
2020
- 2020-12-04 US US17/112,258 patent/US20210087149A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3712131T3 (da) | Neurotensinreceptorligander | |
| DK2859055T3 (da) | Polymercoatings | |
| DK2825087T3 (da) | Otoscanner | |
| EP2809145A4 (en) | CHLOROPLAST TRANSIT PEPTIDES | |
| DK2839013T3 (da) | Ikke-disruptiv-gen-targetering | |
| EP2805877A4 (en) | UNDER HOOD | |
| DK2873977T3 (da) | Dobbeltdækker-rørdispenser | |
| DK2854722T3 (da) | Stomipose | |
| FR2998638B1 (fr) | Raccord | |
| DK2825157T3 (da) | Aminosyrelipider | |
| EP2812047A4 (en) | ACCESS SYSTEM VIA AN OCCLUSION | |
| DK2831122T3 (da) | Anthocyanidin-kompleks | |
| EP2801315A4 (en) | SCANNING ENDOSCOPE DEVICE | |
| DE112012006214T8 (de) | Wulstringwickler | |
| DK2885638T3 (da) | Molekylenet | |
| DK2858657T3 (da) | Feijoafrugtekstrakt | |
| DE102013212400A8 (de) | Abdeckplattenstützbaugruppe | |
| DK2897570T3 (da) | Spin-elueringsrør | |
| DE202012013401U8 (de) | Bioextruder | |
| DK2931704T3 (da) | Thiolfunktionel forbindelse | |
| FR2999675B1 (fr) | Electro-clapet ameliore | |
| BR302012006128S1 (pt) | Configuracao aplicada em chinelo | |
| BR302012006127S1 (pt) | Configuracao aplicada em chinelo | |
| BR302012006126S1 (pt) | Configuracao aplicada em chinelo | |
| BR302012006124S1 (pt) | Configuracao aplicada em chinelo |